Thesis (doctoral)--Universität Hamburg, 1972. / Includes bibliographical references (p. iv-xxxiii).

Thesis (doctoral)--Universität Erlangen.

No description available.

Tse On Ki. / Thesis submitted in: June, 1997. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 97-113). / Abstract also in Chinese. / List of Tables --- p.xiii / List of Figures --- p.xiv / List of Abbreviations --- p.xv / Chapter Chapter 1. --- Introduction to thesis --- p.2 / Chapter 1.1 --- Misoprostol --- p.2 / Chapter 1.1.1 --- Description and History of Drug --- p.2 / Chapter 1.1.2 --- Current Use in Obstetrics and Gynaecology --- p.3 / Chapter 1.1.2.1 --- Termination of Pregnancy (TOP) --- p.3 / Chapter 1.1.2.2 --- Cervix Priming prior to Surgical Treatment of Pregnancy Failure --- p.4 / Chapter 1.1.2.3 --- Medical management of spontaneous abortion --- p.4 / Chapter 1.2 --- Gemeprost --- p.4 / Chapter 1.3 --- Doppler Sonography and Assessment of Blood Velocity --- p.5 / Chapter 1.4 --- Overview of Thesis --- p.5 / Chapter 1.5 --- Aim of this Study --- p.8 / Chapter Chapter 2. --- Physiological and Anatomical Features of Pregnancy --- p.10 / Chapter 2.1 --- Cardiovascular System Changes in Pregnancy --- p.10 / Chapter 2.1.1 --- Changes in the Blood --- p.10 / Chapter 2.1.2 --- Changes in Circulation --- p.11 / Chapter 2.1.3 --- The Distribution of Blood Flow in Uterus --- p.12 / Chapter 2.2 --- Blood Supply to Uterus --- p.13 / Chapter 2.3 --- Pelvic Anatomy in Early Pregnancy via Transvaginal Sonography --- p.15 / Chapter 2.3.1 --- Uterus --- p.15 / Chapter 2.3.2 --- The Adnexa --- p.17 / Chapter 2.3.3 --- Other Pelvic Structures --- p.17 / Chapter Chapter 3. --- Prostaglandins and Analogues --- p.19 / Chapter 3.1 --- Natural Prostaglandins --- p.19 / Chapter 3.2 --- The Source of PGs in Reproductive Organs of Women --- p.19 / Chapter 3.3 --- PGs Synthesis and Metabolism --- p.20 / Chapter 3.4 --- PGE1 Analogue: Misoprostol --- p.21 / Chapter 3.4.1 --- Misoprostol --- p.22 / Chapter 3.4.1.1 --- Pharmacology --- p.22 / Chapter 3.4.1.2 --- Adverse Side Effects --- p.23 / Chapter 3.4.1.3 --- Toxicology --- p.23 / Chapter 3.4.1.4 --- Misoprostol in Obstetrics & Gynaecology --- p.24 / Chapter 3.4.1.4.1 --- To Induce Abortion in First and Second Trimesters --- p.24 / Chapter 3.4.1.4.2 --- Cervix Priming prior to Surgical Evacuation of Uterus --- p.27 / Chapter 3.4.1.4.3 --- Medical Management of Miscarriage --- p.28 / Chapter 3.4.1.4.4 --- Induction of Labour with Dead Fetus --- p.29 / Chapter 3.4.1.4.5 --- Induction of labour --- p.29 / Chapter 3.4.2 --- The Potential Dangers of PGE1 analogues --- p.30 / Chapter Chapter 4. --- Doppler Sonography and Parameter Measurements --- p.34 / Chapter 4.1 --- The Principles of Ultrasound and Doppler Sonography --- p.34 / Chapter 4.1.1 --- The Basic Principles of Ultrasound --- p.34 / Chapter 4.1.2 --- Principles of Doppler Sonography --- p.36 / Chapter 4.2 --- Doppler Mode --- p.39 / Chapter 4.2.1 --- Continuous Wave Doppler Imaging --- p.39 / Chapter 4.2.2 --- Pulsed Wave Doppler Systems --- p.39 / Chapter 4.2.3 --- Colour Doppler Sonography (CDS) --- p.40 / Chapter 4.3 --- The Instrument of Doppler Sonography --- p.40 / Chapter 4.4 --- "Resistance Indices - S/D, PI and RI" --- p.42 / Chapter 4.5 --- Flow Measurement of Uterine artery --- p.44 / Chapter 4.5.1 --- Sampling Sites and Waveforms --- p.44 / Chapter 4.5.2 --- Waveform Components --- p.45 / Chapter 4.5.3 --- Identification of the Main Uterine Arteries --- p.45 / Chapter 4.5.4 --- UA Waveform Changes in Normal Pregnancy --- p.46 / Chapter 4.5.5 --- Factors Affecting the UA Waveforms --- p.48 / Chapter 4.5.6 --- Uterine Artery Resistance in Normal Pregnancy and Labour --- p.49 / Chapter 4.5.6.1 --- Uterine Artery Resistance in Normal Pregnancy --- p.49 / Chapter 4.5.6.2 --- Uterine Artery Resistance during normal labour --- p.51 / Chapter 4.5.7 --- Doppler Measure of Fetal Heart Rate --- p.52 / Chapter 4.6 --- Sonography in Estimation of Gestational Age --- p.53 / Chapter Chapter 5. --- Research Protocol --- p.56 / Chapter 5.1 --- The Ethics --- p.56 / Chapter 5.2 --- Apparatus --- p.58 / Chapter 5.3 --- Drug and Dosage --- p.59 / Chapter 5.4 --- Research Protocol --- p.59 / Chapter 5.4.1 --- Subjects --- p.59 / Chapter 5.4.2 --- Transvaginal Scan --- p.60 / Chapter 5.4.3 --- Parameters Measured --- p.61 / Chapter 5.4.4 --- Misoprostol --- p.65 / Chapter 5.5 --- Data analysis --- p.66 / Chapter Chapter 6. --- Results --- p.68 / Chapter 6.1 --- The Patients' Characteristics --- p.68 / Chapter 6.2 --- The Intra-observer Error --- p.70 / Chapter 6.3 --- Results of Study --- p.70 / Chapter 6.3.1 --- Effect of Misoprostol on the S/D ratio of Both Uterine Arteries --- p.70 / Chapter 6.3.2 --- Effect of Misoprostol on the PI of Both Uterine Arteries --- p.73 / Chapter 6.3.3 --- Effect of Misoprostol on Fetal Heart Rate (FHR) --- p.76 / Chapter 6.3.4 --- Left and Right UA-S/D --- p.78 / Chapter 6.3.5 --- Left and Right UA-PI --- p.81 / Chapter 6.3.6 --- The relationship Between Subgroups --- p.84 / Chapter 6.3.7 --- Side Effects of Misoprostol --- p.85 / Chapter 6.3.8 --- The Changes of UA-S/D and UA-PI According to Gestation --- p.86 / Chapter Chapter 7. --- Discussions and Conclusions --- p.89 / Chapter 7.1 --- Difficulties Encountered during Study --- p.89 / Chapter 7.2 --- Results of Study --- p.90 / Chapter 7.3 --- Implications --- p.94 / Chapter 7.4 --- Summary of Thesis --- p.95 / Chapter 7.5 --- Conclusions --- p.96 / Chapter 8. --- References and Appendix --- p.97

Orientadores: Ricardo Barini, Jose Guilherme Cecatti / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-07T09:44:20Z (GMT). No. of bitstreams: 1 Silva_LucianaVivas_M.pdf: 2243768 bytes, checksum: 779bfadbc13a9b63606a5548362e4609 (MD5) Previous issue date: 2006 / Mestrado / Tocoginecologia / Mestre em Tocoginecologia

Improving the quality of abortion care can reduce stigma, increase access, and enhance knowledge about pregnancy prevention and reproductive health. Midwifery-led medication abortion is considered effective, efficient, accessible, person-centred, equitable, and safe in alignment with the World Health Organization’s framework on quality abortion care. As research on client-centred access to healthcare recommends, Ontario’s expanded midwifery care models are improving the ease with which people can find and use sexual and reproductive services most appropriate to their unique needs. The expanded midwifery care presented in this study demonstrates how midwifery-led medication abortion provides high-quality services, decreases stigma, and improves access to safe, acceptable, and client-centred abortion care, particularly for commonly underserved populations deserving of health equity and Reproductive Justice. / The World Health Organization, the International Confederation of Midwives, and the Canadian Association of Midwives advocate for the inclusion of comprehensive abortion care within midwifery practice. International evidence shows positive outcomes in terms of efficacy, safety, acceptability, and post-abortion contraception uptake when midwives provide abortion services. In Canada, midwifery services are available across various populations, including urban, rural, remote, and Northern areas, suggesting a potential to enhance access and quality of abortion care, particularly for underserved people. Expanding the role of Canadian midwives to include comprehensive abortion care could improve accessibility, address gaps in service provision, support community needs, ensure professional sustainability, foster interprofessional collaboration, and offer continuity of care. Since 2017, the Ontario Ministry of Health has funded Expanded Midwifery Care Models to support midwifery integration, interprofessional collaboration, and delivery of midwifery-led sexual and reproductive care that is not funded under the current payment model. This research explores the individual and shared experiences of midwifery-led medication abortion delivered through Expanded Midwifery Care Models across three distinct regions in Ontario. The study employs interpretive description methodology to understand how midwifery influences the experiences of medication abortion for midwives, collaborating healthcare professionals, and clients. The methodology focuses on exploring how integrating a midwifery model of abortion care supports medication abortion services and promotes Reproductive Justice within primary care settings. By gathering insights from multiple perspectives, the findings hope to inform clinical practice, interest policymakers, and identify outcomes valued by midwives, clients, and healthcare professionals for future research on midwifery-led abortion care. / Thesis / Master of Science (MSc) / Quality abortion care improves the lives, health, and wellness of reproductive-aged people. Abortion is time-sensitive and people face barriers to this care. Reproductive-aged people benefit from healthcare systems that make abortion simple, safe, and effective. Internationally, midwives play a significant role in abortion care by delivering comprehensive services within sexual and reproductive healthcare. In Canada, however, the potential of midwifery in providing abortion care has not been fully realized. As an exception, Ontario’s Expanded Midwifery Care Models (EMCMs) - innovative sexual and reproductive healthcare delivery programs - have made it possible for midwives to provide abortion services. Midwifery-led abortion care in EMCMs includes providing early abortion care in ways that make it easier for people who find it difficult to access care. This research explores and compares the personal and professional experiences of medication abortion care delivered by midwives across three regions in Ontario.